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Summary 
The  spectrum  of the  anti-human  immunodeficiency virus  (HIV)  neutralizing immune  re- 
sponse has  been analyzed by the  production and  characterization of monoclonal antibodies 
(mAbs)  to the viral envelope glycoproteins, gp41 and gp120. Little is known, however, about 
the neutralization mechanism of these antibodies. Here we show that the binding of a group of 
neutralizing mAbs that react with regions of the gp 120 molecule associated with and including 
the V2  and V3  loops,  the  C4  domain and supporting structures, induce the  dissociation of 
gp120 from gp41 on cells infected with the T  ceil line-adapted HIV-1 molecular clone Hxl0. 
Similar to soluble receptor-induced dissociation of gp120  from gp41,  the  antibody-induced 
dissociation is dose- and time-dependent. By contrast, mAbs binding to discontinuous epitopes 
overlapping the  CD4  binding  site  do  not  induce  gp120  dissociation,  implying that  mAb- 
induced conformational changes in  gp120  are  epitope specific, and that  HIV neutralization 
probably involves several mechanisms. 
N 
eutralization  of enveloped  viruses  by  antibodies  is 
fikely to be mediated by at least two mechanisms, in- 
cluding the inhibition of virus binding to its cellular recep- 
tor and interference with viral capsid entry into  the  host 
cell (1). HIV-1 induces an antibody response in infected in- 
dividuals and immunized animals, a component of which is 
neutralizing (2-5). This neutralizing activity appears to be 
directed  predominantly  at  the  surface  (gp120)  envelope 
glycoprotein (6), although neutralization can also be medi- 
ated by a transmembrane glycoprotein (gp41)-specific frac- 
tion of antibodies (7). More recently, the HIV-neutralizing 
response has been dissected by the preparation and charac- 
terization of mAbs  of rodent and human  origin, allowing 
the  identification  of a  number  of neutralization  epitope 
clusters on gp120 and gp41 (8). The known gp120-specific 
neutralizing activity can be divided into responses directed 
to the hypervariable loops V1/V2  (9-14) and V3  (15-27), 
or  to  more  conserved  regions  that  may  contain  hnear 
epitopes such as the C4 domain (28-31), or complex, dis- 
continuous epitopes clustered around the base of the vari- 
able loops that may interfere (32-36) or not (37) with CD4 
binding to gp120. Although considerable success has been 
achieved in characterizing the specificity of the neutralizing 
antibody  response  to  HIV-1,  little  is  understood  of the 
mechanism by which antibodies neutralize this virus. The 
group ofmAbs that interfere with the CD4-gp120 interac- 
tion known as "CD4 binding site (CD4/BS) specific," bind 
to  epitopes  on gp120  that  overlap the  CD4-binding  do- 
main (32-36). Binding of soluble, recombinant gp120 in a 
monomeric form to CD4 is competed by these antibodies 
(34,  36),  implying that their mechanism  of neutralization 
may be based, at least in part, on steric inhibition of virus- 
receptor binding.  It is  unclear,  however, whether results 
obtained with monomeric gp120 are representative of the 
effect of mAb binding to functional, gp41-associated,  oli- 
gomeric gp120, as found on virions and virus-infected cells 
(8). Thus, results  from some laboratories suggest that such 
mAbs are poor competitors of virus binding and may act at 
a postbinding step (McInery, T. L., C. F. Barbas, III, D. IL. 
Burton,  and  N.  J.  Dimmock,  manuscript  submitted  for 
publication), as has been proposed for other enveloped vi- 
ruses  (1). Other mAbs, including those directed to the V1, 
V2,  and V3  loops,  dc~ not  inhibit  the  monomer gp120- 
CD4 interaction, but they interfere with later events that 
may  include  virus-cell membrane  fusion  or  capsid  entry 
into the cell cytoplasm (17, 38). A third group of antibodies 
to linear epitopes in the ectodomain (39,  40)  or cytoplas- 
mic tail (41)  of gp41  are hkely to inhibit virus-cell mem- 
brane fusion, although the nature of the virus-antibody in- 
teraction in the latter case is obscure (42). It therefore seems 
probable that there are various levels at which an antibody 
might inhibit HIV infection of a cell, implying the exist- 
ence of diverse neutralization mechanisms. 
The entry of HIV into  CD4 +  cells  is  thought to  take 
place by "receptor-mediated activation of  virus fusion" (43, 
44). Thus, the binding of HIV to cell-surface CD4 triggers 
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glycoproteins that are believed to result in exposure of the 
fusion  domain  of gp41  and  lead to  virus-cell or cell-cell 
membrane  coalescence  (45,  46).  Conformational  changes 
have been demonstrated in model systems in which a solu- 
ble  form  of CD4  (sCD4) 1  has  been  substituted  for  the 
membrane-anchored molecule (47,  48).  With T  cell fine- 
adapted isolates of HIV-1  (but not with HIV-2 or SIV; 48), 
sCD4 binding to HIV virions or virus-infected cells results 
in the dissociation ofgpl20 from gp41  (49-51). 
Although  envelope glycoprotein subunit  dissociation is 
unlikely to  play a  role in HIV  entry  (52,  53),  it probably 
contributes significantly to virus inactivation (54-56).  The 
relative  inability  of sCD4  to  neutralize  isolates  of  HIV 
(known as primary isolates) that have been passaged only in 
activated PBMC probably results, at least in part, from the 
insensitivity of these viruses to sCD4-induced gp120-gp41 
dissociation  (8,  56,  57).  It  seemed  reasonable  to  suppose 
that certain neutralizing mAbs may inactivate virion infec- 
tivity by a  mechanism  similar to  that  used by sCD4,  and 
that a component of the recently reported resistance of pri- 
mary isolate viruses to neutralization by antisera and mAbs 
(58)  may be a  reduced ability of these reagents to induce 
HIV  glycoprotein subunit  dissociation. In  this report,  we 
have investigated whether this is so. 
The  majority  of well-characterized  neutralizing  mAbs 
that  are  currently  available  have  been  prepared  to  the 
gpl20  glycoprotein  of the  cell  line-adapted  HIV-1  LAI 
isolate. For this reason, we have chosen to study neutraliza- 
tion in a system using the molecular clone Hxl0, a clone of 
the LAI isolate. We have recently shown  that the neutral- 
ization of Hxl0  correlated broadly with  mAb  affinity for 
the oligomeric, gp41-associated form ofgpl20  (59). In this 
study, which uses the same model system, we demonstrate 
that a  group  of gp120-reactive neutralizing mAbs induces 
the  dissociation of the  envelope  glycoproteins on  Hxl0- 
infected cells. Although  it is unclear whether  this activity 
represents  the  dominant  pathway  of H1V  neutralization, 
we suggest that the induction of conformational changes in 
the HIV-1  envelope glycoproteins triggered by mAb bind- 
ing contributes to the neutralization of T  cell line-adapted 
viruses. 
Materials and Methods 
Antibodies.  The anti-gp120/V3 mAbs were from the follow- 
ing sources:  110.I  (60)  from F.  Traincard  (Hybridolab, Pasteur 
Institute, Paris, France); 110.5  (19) front Genetic Systems (Seattle, 
WA); 9284  (18) was  purchased from DuPont  de Nemours  (Les 
Ulis, France); BAT123  (22) was Tanox Biosystems Inc.  (Hous- 
ton,  TX)  and D.  Ho  (Aaron Diamond AIDS Research Center, 
New York).  The  anti-gp120/V2 mAbs BAT085,  G3-136  (10), 
and G3-4 (9), as well as the anti-C4 mAbs G3-42, G3-519, G3- 
299, and G3-536 (28, 30) were also from Tanox and D. Ho. The 
human mAbs specific for complex epitopes 15e,  21h  (31),  48d, 
I  Abbreviations used in  this paper: GM,  growth  medium;  sCD4, soluble 
CD4; WB, wash buffer. 
and  17b  (37) were from J.  Robinson (Department of Pediatrics, 
University of Connecticut, CT), and IgGl-b12 was from D. Bur- 
ton  (The  Scripps Research Institute, La Jolla, CA) was  selected 
from a recombinant Fab library (34) and subsequently engineered 
into  an  IgG molecule  (35).  The  human  anti-gp41  mAb 50-69 
(61)  was  from  S.  Zolla-Pazner  (New  York  University,  New 
York). 
Ceil Culture and  Virus Infection.  H9  cells  (from  R.  C.  Gallo, 
NIH,  Bethesda, MD)  were  cultured in growth medium  (GM), 
RPMI/10%  FCS in the presence of 5%  C02.  Infection of H9 
cells  with  supematant  containing infectious virus  of the  Hxl0 
clone  of HIV-1  (62,  from  A.  Fisher (Hammersmith  Hospital, 
London, UK) was as follows: 1 million cells in 1 ml were exposed 
to ~104 TCIDs0 of virus for 2 h at 37~  After washing, the cells 
were resuspended in GM and cultured for 6-8 d.  At this time, 
100% of the cells expressed large amounts of viral envelope gly- 
coproteins, but no CD4, as detected by immunofluorescent stain- 
ing and flow cytometry using mAbs directed to  the  gp120  V3 
loop and domains 1 and 4 of CD4, respectively. 
Measurement of mAb-induced gp 120 Dissociation from  Virus Parti- 
cles.  H9 cells infected with Hxl0 were metabolically labeled on 
day  8  after  infection,  this  time  point  having  been  previously 
shown to yield the highest amount of cell-free virus. Labeling was 
carried out as follows: the infected cells were starved in methio- 
nine- and cysteine-free RPMI medium for 30 min before being 
resuspended at a concentration of 3  X  106 cells/ml in the same 
medium containing 3% dialyzed FCS,  [3SS]methionine/[3SS]cys- 
teine  mix  (EXPRE  3sS3SS Protein  Labeling Mix;  DuPont  de 
Nernours)  with  the  addition of extra  [3SS]cysteine (DuPont  de 
Nemours) to give a final activity of 100 IxCi for each amino acid. 
After 18 h of culture, the cells were pelleted, the supernatant was 
recovered and filtered through a 0.45-p~m pore size cellulose ace- 
tate filter (Acrodisc; Gelman Sciences, Ann Arbor, MI), then cen- 
trifuged  for  20  rain  at  70,000  rpm  in  a  centrifuge  (TL100; 
Beckman, Gagny, France). For the analysis of envelope glycopro- 
tein  subunit  dissociation,  the  virus  pellet  was  resuspended  in 
RPMI/10% FCS containing mAb (40 Ixg/ml) or sCD4 (13.3 txg/ 
ml) in a total volume of i00 btl, and incubated at 37~  for 2 h. 
The amount ofgpl20 released from the virion surface  was mea- 
sured  essentially as  reported by Willey et  al.  (63).  Briefly, the 
mAb- or sCD4-treated samples were centrifuged in a microfuge 
at 13,000  rpm for 90 rain at 4~  to gently pellet the virus. 90 Ixl 
of the supematant was removed, and the virus pellet was washed 
with the addition of 40 Ixl RPMI, and recentrifuged as before for 
an additional 40 rain. 40 Ixl of the supematant was removed and 
pooled with  the  original 90  ILl. The  pelleted virus was  resus- 
pended in 120  Ixl of RPMI, and both the supernatant and virus 
were resuspended in 600 p,1 oflysis buffer (50 mM Tris, 150 mM 
NaC1,  5 mM EDTA, 1% NP-40, and 0.15% SDS), and denatured 
by boiling for 5  nfin.  The  lysates  were  precleared overnight at 
4~  with protein A-Sepharose beads (Pharmacia Fine Chemicals, 
Piscataway,  NJ), then viral proteins were immunoprecipitated for 
2 h at 4~  with the same beads precoated with human HIV im- 
mune globulin (obtained from the NIH AIDS Reagent and Ref- 
erence Program, Bethesda, MD; 64). Pelleted beads were washed 
three times with lysis buffer and boiled for 3  min  in  reducing 
sample buffer. Immunoprecipitated proteins were separated on an 
SDS 8% acrylamide gel. The gel was dried and analyzed by fluo- 
rography using a Fugix Bas 2000 Bio-image Analyzer (Fuji, Ja- 
pan), and the intensity of the gp120 bands was quantified. The gel 
was then autoradiographed at -70~ 
Analysis of Antibody Binding  by Flow Cytometry.  The  analysis 
was  carried out essentially as previously described (59).  Briefly, 
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washed twice in 1<PMI/5% FCS, and were resuspended at a con- 
centration of 5  ￿  107 cells/ml. 20  I*l ofmAb previously diluted 
in PBS/1% FCS  (wash buffer [WB])  was added  to 20  I*1 of cell 
suspension  in  a  U-bottomed,  96-well microtiter plate,  and  was 
incubated with agitation at 37~  for 2 h. The cells were pelleted, 
and the supernatants were harvested for analysis  of HIV-l-soluble 
gp120 (see below). The cells were washed three times in ice-cold 
WB, then fixed in WB  +  0.5% formaldehyde overnight at 4~ 
After two further washes in WB, the cells were divided into two 
equal samples: one sample was stained with 50 I*1 ofbiotinylated 
anti-gp41 mAb 50-69 at 10 I~g/ml for 1 h at 4~  before washing. 
Subsequently, both samples were stained for 1 h  at 4~  with the 
appropriate  dilution  of  fluorochrome-conjugated  second  layer 
antibody;  the  first  with  streptavidin-PE,  the  second  with  anti- 
human  or anti-mouse  conjugated  to  PE  (all  obtained  from  Im- 
munotech SA, Marseille, France). The cells were washed twice as 
before, then analyzed by flow cytometry using a FACScan  |  (Bec- 
ton  Dickinson  &  Co.,  Mountain  View,  CA)  with  Consort  30 
software. 
Kinetic  analysis  of mAb  and  sCD4  binding  to  HIV-infected 
H9 cells was carried out essentially as described above, except that 
the concentration of ligand was  kept constant  (67  nM),  whereas 
the incubation time was varied. Briefly, 20  b~l previously diluted 
mAb  or sCD4 was  added to 20  b~l of cells at a concentration of 
5  X  107/nil in a U-bottomed, 96-well microtiter plate, and incu- 
bated with agitation at 37~  At the time points indicated,  10 ~1 
of cell  suspension  was  removed,  then  the  cells  were  washed, 
fixed, stained, and analyzed as described above. 
ELISA Assays for mAb-induced  gp120 Dissociation.  Release  of 
gp120 from the surface of Hxl0-infected, mAb-treated cells was 
determined  as  follows:  1  million cells in 40  I~l previously incu- 
bated at 4  or 37~  for 2  h  with mAb as described above for the 
mAb-binding  studies  were  pelleted,  and  the  supematants  were 
harvested and spun at 12,000 vpm for 2 min in microfilters (Spin-X; 
Costar, Brumath,  France)  to remove remaining cells and cell de- 
bris, and 4.5  ILl of a  10% solution of NP-40 was added.  To pre- 
vent interference with the gpl20 detection, the samples were de- 
natured to eliminate prebound mAb. Thus, SDS and dithiothreitol 
were added  to 20  wl of supernatant  to yield final concentrations 
of 1% and 50 mM, respectively. After boiling, the treated super- 
natants  were then diluted in  180  wl of TBS/FCS (0.1%)/NP-40 
(0.1%).  100  I~1 was  then  added  to  duplicate  wells of an  ELISA 
plate precoated with the gpl20 capture antibody D7234. The de- 
tection and calibration of denatured gp120 in the supematant was 
carried  out  as previously described  (60),  using the  murine  mAb 
B13  (from  G.  Lewis,  University of Maryland  Medical  School, 
Baltimore,  MD),  which  reacts  preferentially  with  denatured 
gp120 (60). 
HIVNeulralization Assays.  To  analyze  mAbs  for  neutraliza- 
tion activity, we used  an assay  based  on infection of HeLa  cells 
expressing  human  CD4  and  the  HIV LTR  gene  fused  to  lacZ 
(65),  which we have previously desribed  (59).  Infection of these 
cells with HIV leads to the production of the viral TAT protein, 
which  transactivates  the  transfected  LTR  and  activates  the  lacZ 
gene; detergent lysis of the cells is then followed by addition of 
a soluble substrate.  The advantage  of this assay system is that in- 
fection of the  cells can be detected within 24-36  h  of infection 
(approximately  one cycle of replication with the moi used),  and 
reduction in infectivity can be quantitatively assessed  by measure- 
ment of the OD. The assay was essentially the same as that previ- 
ously  described,  with  the  exception  of  the  modification  for 
ELISA readout;  the modification is as follows. 24-36  h  after in- 
fection, the medium was  aspirated  and the cells were lysed in a 
solution of PBS containing 0.5%  NP-40.  An equal volume of a 
solution  containing  16  mM  chlorophenol  red  [3-D-galactopy- 
ranoside  (CPR.G;  Boehringer  Mannheim,  Meylan,  France)  was 
added; after 30 min of incubation with the substrate  at 37~  the 
OD  was  read  at  OD550n  m.  Percentage  inhibition  was  calculated 
using the formula 100  -  {(t -  c)/(m -  c)  ￿  100}, where t repre- 
sents  the  OD  signal  for the  test  sample,  c represents  the  back- 
ground signal in the absence of virus, and m represents the maxi- 
mum signal obtained with vires but no inhibitor. 
Results 
mAb Epitope Specificity.  The  mAbs  used  in  this  study 
represent  the  dominant  gp120-specific  component  of the 
currently  recognized  spectrum  of HIV-neutralizing  activ- 
ity. As shown in Fig.  1,  the mAbs can be divided into two 
groups:  those  recognizing essentially linear epitopes,  com- 
prising the variable loops V1/V2  and V3,  and the relatively 
conserved  C4  region,  and  those  recognising complex,  dis- 
continuous  epitopes  that  are  overlapping  or  nonoverlap- 
ping  for  the  CD4-binding  site.  The  V1/V2  and  V3  loop 
Figure  1.  Epitopes  of mAbs used  in this study.  The epitopes  for the 
V2,  V3,  and  C4 murine mAbs are represented  as linear sequences,  and 
were taken from the following sources: BAT085, G3-4, and G3-136 (11); 
9284,  110.5, BAT123,  and  110.1 (18, 29, 22, and 60 respectively); G3- 
42,  G3-299,  G3-536,  G3-519  (28, 30). The discontinuous  epitopes  for 
the  human  mAbs  were  mapped  by  site-directed  mutagenesis.  A  small 
open box represents  an  amino acid substitution  that  partially  (50-95%) 
abrogates mAb binding;  a small closed box represents an amino acid sub- 
stitution that completely (>95%) abrogates binding; a large open box rep- 
resents two or more amino acid substitutions that partially (50-95%) abro- 
gate binding,  and a large closed box represents two or more amino acid 
substitutions that completely  (>95%)  abrogate binding.  Epitope mapping 
data were taken from the following sources: 48d and 17b (37); 15e, 21h, 
and sCD4 (33); IgG1 b12 (34). 
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posed on oligomeric gp120;  mAbs binding to flanking re- 
gions on these loops are either poorly exposed or not ex- 
posed on the glycoprotein oligomer (59, 60). Additionally, 
all of these mAbs have been shown  to  neutralize cell-free 
Hxl0 virus (59). Experiments that we have recently carried 
out  aimed at  estimating mAb  association and  dissociation 
rates  from  oligomeric gp120  suggested that  certain  mAbs 
modulated  gp120-gp41  dissociation  (59).  To  investigate 
this more  fully, we  carried out  studies  to  compare  sCD4, 
which  is known  to  disrupt efficiently the  gp120-gp41  in- 
teraction with the anti-gp120 mAbs. 
mAb-induced gp120 Dissociation  fiom Hx l O Virions.  Met- 
abolically labeled virus was concentrated by centrifugation, 
incubated with or without  mAb or sCD4,  pelleted, dena- 
tured, and the quantity of gp120 present in the supernatant 
or pellet was determined by immunoprecipitation, autora- 
diography and fluorography. The denaturation step was in- 
cluded to  ensure  that the  Igs present in the  reaction were 
dissociated from gp120  and inactivated, so as to  avoid any 
potential  interference  with  the  precipitation  step.  In  this 
experiment,  we  compared  two  mAbs,  G3-4  and  9284, 
which  bind  to  the  V2  and  V3  loops,  respectively,  with 
sCD4. As shown in Fig. 2 A, gp120 was found in both the 
supernatant and the viral pellet, and as expected, p24 and to 
a lesser extent other virion proteins were found in the virus 
pellet. Some p24 was also present in the supernatant,  sug- 
gesting that  soluble p24  is probably a  contaminant  in  this 
system; similar observations have also been made by others 
(63).  Levels of p24 remained constant in the samples, con- 
firming that the  observed changes  in gp120  concentration 
were  not  a  result of variation in  the  quantity of virus be- 
tween  samples.  Visual  inspection  of the  gp120  bands  re- 
vealed that in the presence ofsCD4 and the V3 mAb 9284, 
there was a striking diminution in gp120 signal in the virus 
pellet and a  corresponding increase in the supernatant.  To 
quantify this, the amount  of gpl20 in the supernatants and 
viral pellets was  determined  by phosphor  imaging of the 
dried gel, and is represented in Fig. 2  B.  The total amount 
ofgpl20  (virus +  supernatant) remained constant under all 
conditions,  except  the  4~  incubation,  in  which  it  was 
higher; this may reflect a lower level of gpl20 degradation 
at this temperature. Incubation of the virus alone at 4~  in- 
duced some spontaneous  gp120  dissociation that increased 
subtly at 37~  although  the  levels of gpl20  recovered in 
the  supernatant  were  similar. Preincubation  of virus with 
266 nM (13.3 Dg/ml) ofsCD4 for 2 h  at 37~  increased by 
41%  the  amount  of soluble gp120  in the  supernatant,  and 
decreased by 32% virion-associated gp 120. Similarly, prein- 
cubation with 266 nM (40 b~g/ml) ofmAb 9284 resulted in 
a 41% increase in supernatant gp120 and a 29% decrease in 
virion-associated gp120.  By contrast, the V2 mAb G3-4 at 
the  same  concentration  increased  supernatant  gp120  by 
only 16% and did not significantly alter gp120 dissociation 
from the virus compared to that lost spontaneously at 37~ 
These  results  demonstrate  that  at  the  concentration 
tested, a V3 loop mAb was able to mimic sCD4 in its abil- 
ity to induce gp120 dissociation from virion gp41  at 37~ 
Figure  2.  mAb-induced gpl20 dissociation from Hxl0 virions. Meta- 
bolically labeled virus in supematants from Hxl0-infected H9 cells was 
pelleted by ultracentrifugation, then resuspended in the presence or ab- 
sence of sOD4 or mAbs. After incubation for 2 h at 4~  or 37~  the su- 
pernatant was separated from the viral pellet. Protein in the pellet and su- 
pernatant  was  denatured  to  destroy  mAb  or  sCD4 interactions with 
gp120, and the gp120 was precipitated with a purified polyclonal anti- 
HIV-1 antiserum. After denaturing SDS-PAGE, the gel was dried and au- 
toradiographed. (A) The five lanes on the left show viral proteins precipi- 
tated from the supernatant, and the five lanes on the right show proteins 
from the viral pellet. (B) The quantification of mAb- and sCD4-induced 
gp120 dissociation  from Hxl0 virions. The gp120 bands shown in the au- 
toradiograph in A were quantified by phosphor imaging, and displayed as 
units of phosphor-stimulated luminescence (PSL). 
It  was  important  at  this  point  to  determine  the  epitope 
specificity intrinsic to the mAb-induced gp120 dissociation 
and to investigate whether (a) mAb-induced gpl20 dissoci- 
ation was  dose and time dependent;  and  (b)  mAb binding 
induced exposure of previously masked gp41  epitopes. To 
476  Neutralizing Antibodies Induce HIV-I gpl20 Dissociation investigate  these  parameters,  we  decided  to  study  virus- 
mAb interactions  using infected cells,  since  the analysis of 
mAb binding  and hgand-induced  conformational  changes 
in multiple  samples  is  facihtated in such a  system  (42,  47- 
50, 59). 
mAb-induced gp120  Dissodation from  Hx l O-infected Cells. 
We have previously shown that HIV-infected H9 cells ex- 
press  readily  detectable  gpl20/gp41  complexes  at  the  cell 
surface,  the  majority  of which  probably  represent  func- 
tional  envelope  glycoprotein  ohgomers  on  mature  virus 
particles  (47, 48, 59). To study in more detail the ability of 
mAbs  to  induce  gpl20  dissociation,  Hxl0-infected  H9 
cells were  incubated  with  gpl20  mAbs or sCD4,  and  the 
following  parameters  were  measured:  (a)  binding  of the 
mAbs  to  the  virus-infected  cell  surface;  (b)  exposure  of a 
gp41  epitope that is normally masked by gpl20; and (c) ac- 
cumulation  of soluble  gpl20 in the supernatant.  As in the 
previous experiment,  we denature the supernatant proteins 
after treatment  of the cells  with sCD4 or mAbs to obviate 
any interference  of gpl20-bound ligand in the ELISA de- 
tection  test.  We  have  previously  demonstrated  that  gp41 
exposure  correlates  with  gpl20  dissociation  (47,  48),  and 
therefore  have used  this  marker as further confirmation  of 
the mAb-mediated conformational changes taking place in 
the viral envelope  glycoproteins.  Fig.  3  shows mAb bind- 
ing to infected cells, gp41  exposure, and soluble gpl20 re- 
leased into  the  supernatant  at one mAb-sCD4 concentra- 
tion  (67  nM).  There  was  considerable  variation  in  the 
fluorescence signals  obtained after binding of the  different 
mAbs.  This  reflects  a  combination  of the  differences  in 
mAb association rate for oligomeric gpl20  (59),  the possi- 
bility that the Bm~x value is different for the different mAbs, 
and  the  fact  that  three  different  staining  conjugates  were 
used; anti-mouse PE, anti-human PE, and a two-layer de- 
tection  for sCD4  consisting  of anti-CD4  mAb  L120  (47) 
followed by anti-mouse PE. A precise comparison of abso- 
lute numbers  of mAb molecules bound per infected cell is 
therefore  unfeasible  under  these  conditions.  Confirming 
our previous observations of relative binding activities (59), 
however, V3 loop mAbs bind well,  mAbs to certain com- 
plex epitopes bind with intermediate  efficiency, and certain 
mAbs to  the  V2  and  C4 regions bind poorly under these 
conditions.  Comparison  of the  values  obtained  for  gp41 
exposure  and  gp120  accumulation  in  the  supernatant  re- 
veals a broad correlation, confirming that these two param- 
eters  are  related.  By  contrast,  a  comparison  of the  values 
representing  the  total  quantity  of mAb bound with  those 
representing gp41  exposure and dissociated gp120 does not 
reveal a simple relationship;  certain mAbs such as 15e, 21h, 
and IgG1 b12, which bind relatively well to the cells  at the 
concentration used,  induce little  or no gp41  exposure  and 
gpl20 dissociation, whereas others, such as 9284, BAT123, 
and 48d, induce strong gp41 exposure and gpl20 release at 
37~  These experiments have been repeated at 4~  and as 
with  sCD4-induced  conformational  changes,  little  or  no 
gpl20  dissociation  and  gp41  exposure  were  seen  (results 
not  shown).  To  confirm  the  specificity  of  the  mAb- 
induced conformational changes, we measured the effect of 
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Figure 3.  mAb binding and mAb-induced gp41 exposure and gpl20 
dissociation. (A) The binding to Hxl0-infected cells of  a panel of  neutral- 
izing gpl20 mAbs, as was analyzed  by indirect immunolluorescence and 
flow cytometry. Hxl0-infected cells were incubated for 2 h at 37~  with 
mAbs or sCD4 at a concentration of  67 nM. Cells were pelleted, washed, 
fixed, and stained with anti-mouse or anti-human IgG coupled to PE. 
Each bar represents the mean fluorescence intensity for 10,000 accumu- 
lated events. (13) The binding ofa biotinylated anti-gp41 mAb to the same 
Hxl0-infected cells used in A. mAb-stained cells were fixed as described 
for A, then incubated for 1 h with 10 Ixg/ml of biotinylated gp41 mAb 
50-69, which  recognizes an  epitope constitutively masked by gpl20. 
Binding of the biotinylated gp41 mAb was revealed by incubation of the 
cells with streptavidin-conjugated PE, then analysis by flow cytometry as 
described above. (C) The release of  soluble gpl20 from the surface of  the 
mAb-treated, Hxl0-infected ceils. After the mAb treatment as described 
for A, cells were pelleted and the supernatants were recovered. After cen- 
trifugation through Spin-X filters to remove cellular debris, supernatants 
were denatured, and  the  concentration of gp120 was  determined by 
ELISA. Each bar represents the mean of three replicate wells, and the er- 
ror bars represent +  1 SD. 
mAb concentration on gpl20 dissociation and gp41  expo- 
sure at 37~ 
Dose Response of gp120  Dissociation from  HxlO-infected 
Ceils.  mAbs or sCD4 were titrated from 30 or 10 p.g/rnl, 
respectively,  (200  nM)  to  0.014  or 0.004  p~g/ml,  respec- 
tively (~0.1  nM),  and incubated with the infected cells as in the previous experiment. As shown in Fig. 4, mAb bind- 
ing  was  dose  dependent,  and  saturation  binding  was 
achieved  with  mAbs  specific  for  the  V3  loop  and  some 
complex  epitopes,  in agreement with  our previous report 
(59). By contrast, equilibrium-binding conditions were not 
attained with V2 mAbs, with C4 mAbs other than G3-42, 
and with the CD4/BS  mAbs  with the exception of tgG1 
b12, in accord with the proposal that the majority of these 
mAbs  associate  relatively  slowly  with  oligomeric  gp120 
(59).  Gp41  exposure and gp120 dissociation were  broadly 
related for all  mAbs,  although gp41  exposure appeared  to 
be the more sensitive assay for mAb or sCD4-induced con- 
formational  changes.  V2  mAbs  induced tittle  gp41  expo- 
sure <10 nM, and no detectable gp120 dissociation <100 
nM;  no obvious correlation could be  established between 
the  level  of  gp41  exposure/gp120  dissociation  and  the 
mAb-binding activity since the signals  were  generally too 
low  to  allow  precise  interpretation.  By  contrast,  the  V3 
mAbs were more potent in all respects;  binding was of high 
relative affinity, and gp41  exposure and gp120 dissociation 
were  readily detectable  at 0.3  nM and between  1 and 30 
nM, respectively.  The binding of the C4  mAbs was vail- 
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Figure 4.  Dose dependence of 
gp41  exposure and gpl20  disso- 
ciation. Hxl0-infected cells were 
incubated with sCD4 or mAbs as 
described for Fig.  3,  except that 
the ligands were titrated from 0. I 
to  200  nM.  The processing and 
analysis of the cells and superna- 
rants were as described in Fig. 3. 
The left column represents n~b 
or sCD4 binding to the infected 
cells,  the  central column shows 
the  binding  of  a  biotinylated 
gp41  mAb to  the infected  ceils, 
and the fight column shows the 
amount  of  soluble  gpl20  de- 
tected in the supernatant. able;  G3-42 saturated  at  30 nM,  whereas the  other mAbs 
did  not  achieve  saturation  under  these  conditions.  Gp41 
exposure correlated broadly with binding, and all C4 mAbs 
induced gpl20 dissociation.  The two mAbs reactive with 
complex  epitopes  nonoverlapping the  CD4-binding  site, 
17b and 48d,  bound with intermediate  affinity  to the  in- 
fected cells, saturating at ~30--100 nM. 48d was more po- 
tent  at  inducing gp41  exposure,  and both mAbs induced 
gp120 dissociation.  The  CD4-binding site  mAbs  15e  and 
21h bound with relatively low affinity  compared to IgG1 
b12,  which  saturated  at  ~10  nM.  By  contrast  with  the 
other mAbs, none of the three CD4/BS mAbs was able to 
induce gp41  exposure and gpl20 dissociation at any con- 
centration  tested.  We  tried  concentrations  of up  to  600 
nM, but saw no effect of these three mAbs on the destabili- 
zation of the gpl20-gp41 interaction (data not shown). Fi- 
nally,  in  confirmation  of previous  studies,  soluble  CD4 
bound well to  the  Hxl0-infected cells  and induced gp41 
exposure  and gp120 dissociation.  The  extent  of these  ef- 
fects  appeared  similar  in  magnitude  to  those  induced by 
certain V3 and C4 mAbs.  It should be noted that the in- 
duction  of  gp120  dissociation  will  alter  mAb-binding 
curves as previously demonstrated for sCD4  (47-49,  54), 
preventing  precise  analysis  of binding  parameters.  This 
source  of inaccuracy should  be  taken  into  consideration 
when  interpreting  the  half-maximal  binding  data  for the 
gp120 mAbs taken from Fig.  4 and presented in Table  1. 
Inspection of the values in Table 1 reveals a broad relation- 
ship  between  the  relative  binding  affinity  of the  gp120 
mAbs  (excluding the  CD4/BS mAbs)  and their ability to 
induce gp41 exposure. Those with the lowest half-maximal 
binding values  for binding to  gp120 also  gave the  lowest 
values  for  gp41  exposure,  and  thus  the  highest  affinity 
mAbs induced gp41 exposure most efficiency. 
Time Course of mAb-induced gp120 Dissociation.  Hxl0- 
infected H9 cells were incubated with a fixed concentration 
of mAb or sCD4 (67  riM)  for different times at 37~  the 
cells were fixed, and mAb binding and gp41 exposure were 
subsequently evaluated. Fig. 5 shows that the rate of associ- 
ation was variable,  and it was ranked as follows with mAb 
9284 having the most rapid kinetics; 9284 (V3) >sCD4 = 
IgG1  b12  (CD4/BS)  =  48d  (complex)  >G3-42  (C4) 
>G3-136 (V2).  With the exception of the CD4/BS mAb 
IgG1 b12, which did not significantly  increase the gp41 ex- 
posure above background, the  rate  of gp41  exposure was 
similar  to  the  mAb-binding  pattern;  sCD4  induced  the 
most rapid response, then 9284 =  48d >G3-42 >G3-136. 
In  general,  mAb-induced  gp41  exposure  was  somewhat 
slower than that  obtained with  sCD4,  and it  appeared to 
increase linearly with time, achieving a maximal extent by 
160 min after addition of the ligand.  The relationship be- 
tween the time for the mAbs to achieve equilibrium bind- 
ing and their ability  to induce gp41 exposure suggests  that 
the  mAb association rate  may be  a  determinant  of mAb- 
induced  conformational  changes  in  the  HIV-1  envelope 
glycoproteins. 
mAb Neutralization  ofHIV-1 HxlO.  We  have  analyzed 
previously (59) the neutralization activity for Hxl0 of the 
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majority  of mAbs  used  in  this  study.  Here  we  have  re- 
peated  this  analysis  using  the  same  system,  but  with  an 
ELISA-based readout, and the data are summarized in Ta- 
ble 1. We found some differences between the two studies 
in  the  50%  inhibitory doses  for certain  mAbs; it is  likely 
that this represents batch-to-batch variation in mAb stocks 
and a small difference in sensitivity  between the assays. De- 
spite  these differences,  we found essentially  the same  rank 
order  in  terms  of the  ability  of the  mAbs  to  neutralize 
Hxl0. 
To  establish  whether  a  relationship  exists  between  the 
neutralization  activity of a  mAb and  its  ability  to  induce 
gp41  exposure  and  gp120  dissociation,  we  compared the 
concentrations  required  for  half-maximal  inhibition  with 
those giving half-maximal gp41 exposure. We were unable 
to  compare the  same  set  of values  for gp120 dissociation 
since maximal dissociation was rarely achieved under  the 
conditions used; we thus make the assumption that in gen- 
eral terms, the level of gp41 exposure is indicative of, and 
correlated with gp120 dissociation.  Within certain groups, 
there was a broad relationship between neutralization and 
gp41  exposure; the V3 loop mAbs, the C4-reactive mAbs 
Table 1.  Comparison  of mAb Binding, Neutralization, and gp41 
Exposure Parameters 
Half-maximal  Neutral-  Half-maximal 
Region  mAb  binding  ization  gp41  exposure 
nM  nM  IDso in nM  nM 
V2  G3-136  20*  18.5  10 
G3-4  >70'  20  > 100~ 
BAT085  >70  125  >100 
V3  110.5  0.07  0.04  2 
9284  0.07  0.17  3 
BAT123  0.08  0.03  10 
110.I  0.45  1.3  3 
C4  G3-42  0.5  0.5  10 
G3-299  3.0  2.5  40 
G3-519  >50  70  100 
G3-508  >50  37  >100 
Complex  48d  2.5  0.3  8 
17b  10  0.8  20 
CD4/BS  15e  10  0.8  -IL 
21h  7  8.3  - 
IgG1 b12  1  0.3  - 
CD4  sCD4  0.8  0.2  1.5 
*Results are the mean of two to five independent experiments for each 
parameter and each mAb. 
*Half-maximal binding values could be calculated for mAbs for which 
saturation binding was not achieved. 
~Half-maximal gp41 exposure could not be calculated for mAbs for 
which saturation gp41 mAb binding was not achieved. 
IINo significant gp41 exposure was seen at any mAb concentration that 
was tested. 120]  A 
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Figure  5.  Time  course ofmAb binding and gp41 exposure, mAbs and 
sCD4 at a concentration of 67 nM were incubated with Hxl0-infected 
H9 cells at 37~  At the time points shown, aliquots of the samples  were 
removed, washed once, and immediately fixed in 0.5% formaldehyde. 
The samples were washed and stained with the appropriate conjugated 
fluorochrome as described for Fig. 3. (A) Neutralizing mAb binding; (B) 
biotinylated gp41 mAb binding. 
G3-42  and  G3-299,  and  complex epitope-reactive mAbs 
48d and  17b were strong neutralizers and gave high gp41 
exposure. The level ofgp41 exposure, however, did not al- 
ways  correlate with  neutralization  potency.  For example, 
the V3 loop mAbs BAT123 and 110.5 are the most potent 
neutralizers, but do not induce greater gp41  exposure than 
other V3  mAbs such  as  110.I  and  9284,  which  are more 
weakly neutralizing. Thus, factors other than the induction 
of  conformational  changes  and  gp120  dissociation  may 
contribute to the neutralization efficiency of non-CD4/BS 
mAbs. The rate of association may, for example, influence 
the mAb neutralization efficiency (59). 
Discussion 
Our results demonstrate that the binding of neutralizing 
mAbs at 37~  to certain regions of HIV-1  gp120 induces 
the dissociation of gp120  from gp41, leading to the shed- 
ding of gp120--mAb complexes and the exposure of a pre- 
viously masked  epitope  of gp41.  The  induction  of such 
conformational changes in the viral envelope glycoproteins 
by soluble receptor molecules is well characterized (42-51), 
implying that  the  binding  of mAbs to  specific regions of 
gp120 may mimic, at least in part, the gp120-receptor in- 
teraction. 
In a previous study in which we analyzed the dissocia- 
tion  of gp120  induced by sCD4  (49),  we were unable  to 
demonstrate a similar activity for the V3 loop mAb 110.5, 
which in the present study induces gp120 dissociation. It is 
unclear why there is a discrepancy between these two data 
sets, although in the previous study, the gp120-mAb complex 
was not denatured as in the current study, thus the bound 
110.5 might have interfered with the detection system. 
We have been unable to  demonstrate formally that the 
dissociation of gp120 is a dominant pathway of neutraliza- 
tion  by non-CD4/BS  mAbs;  despite  a  broad  correlation 
between gp41  exposure, gp120 dissociation and neutraliza- 
tion,  we  cannot rule  out  the  possibility that  other factors 
may play an equal or more important role. Evidence from 
studies  with  other  reagents  and  viruses,  however,  lends 
support to the idea that gp120 dissociation is an important 
pathway ofT cell line-adapted HIV-1 neutralization. HIV-1 
inactivation by sCD4 has been shown to be comprized of 
two components; competition for membrane CD4 binding 
and  gp120  dissociation.  Although  it  is  not  certain  that 
gpl20 dissociation is the dominant pathway of virus inacti- 
vation  by  sCD4,  the  fact  that  it  is  irreversible  argues 
strongly for an effect on infectivity that is more profound 
than that of competition for receptor binding (49,  54,  56). 
Support for this comes from studies showing that compared 
to HIV-1, sCD4 is poorly able to neutralize the related im- 
munodeficiency viruses HIV-2 and SIV (48, 66-68) despite 
the fact that the relative affinities ofsCD4 for HIV-1, HIV-2, 
and SIV oligorneric gp120 differ by less than one order of 
magnitude  (48).  One  factor determining  HIV-2 and  SIV 
resistance to sCD4 neutralization  may be that the  associa- 
tion  between  their  surface  and  transmembrane  glycopro- 
teins is strong, and unlike  HIV-1, sCD4 binding does not 
lead  to  their dissociation  (48,  69).  Indeed,  several studies 
have demonstrated that sCD4 binding to HIV-1  and SIV 
enhances  virus  infectivity and  fusogenicity  (69-72).  Very 
recently, two studies have demonstrated that mAbs that are 
neutralizing  for  some  primary  isolates  of HIV-1  are  en- 
hancing for others  (73,  74).  Thus,  by analogy with  sCD4 
neutralization or enhancement ofT cell line-adapted HIV-1 
and  HIV-2/SIV,  respectively,  primary  isolates  of HIV-1 
may be neutralized  or their infectivity may be enhanced, 
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lope glycoproteins. 
The  regions  of gp120  implicated in  the  mAb-induced 
conformational changes appear to be defined by three lin- 
ear epitope clusters (V2, V3, and C4) and two related, dis- 
continuous  epitopes  recognized  by  mAbs  17b  and  48d. 
The binding  of these  latter two  mAbs is  reduced  by the 
substitution  of amino  acids  in  several  regions,  including 
changes in and around the  CD4-binding site  (see  Fig.  1), 
although the binding of these mAbs is not inhibited by pre- 
incubation of g  p120 with sCD4 (37,  75).  Neither the V1/ 
V2 nor the V3 loops are required for binding of these two 
mAbs  (75),  although  competition was  seen between  48d 
and 17b and certain mAbs reactive with the V1/V2 and V3 
loops and the C4 region (Moore, J., personal communica- 
tion).  Since both sCD4 binding to gp120  and removal of 
the V2 loop by mutagenesis increases the  exposure of the 
17b and 48d epitopes (75),  and a substitution at the base of 
the  V2  loop  abolishes  mAb  binding  (37),  it seems likely 
that a component of their epitopes is located close to the 
base of the V2 loop. There is now a considerable body of 
evidence  demonstrating physical interactions  between  the 
V2  and V3  loops  (76),  V2  and  C4  (11),  V3  and  C4  do- 
mains  (30,  77,  78),  and all three domains (76).  Moreover, 
the  rearrangement  of these  domains  is  implicated  in  the 
conformational  changes  induced  by  sCD4  binding  to 
gp120, and is therefore likely to be important in the HIV- 
cell fusion process (47,  48, 76).  It seems reasonable to pro- 
pose, therefore,  that the V2/V3/C4  complex on gp120  is 
an element involved in HIV fusion, and that the binding of 
ligands to  this  complex may inactivate viral infectivity by 
inappropriate or incomplete triggering of virus fusion. 
By contrast with the effect of mAb binding to the V2/ 
V3/C4  domains,  the  interaction of mAbs with the  CD4- 
binding site did not induce the dissociation of gp120 from 
gp41; we have therefore defined two functionally distinct 
mAb clusters. This implies that there are likely to be at least 
two different mechanisms of neutralization that are depen- 
dent on the epitope specificity of the neutralizing ligand. It 
is  interesting  to  note  that  despite  the  similarity between 
CD4-binding site mAbs and CD4 in terms of contact resi- 
dues on gp120, these mAbs do not induce the same con- 
formational changes in oligomeric gp120 as does sCD4. In- 
deed, the effect of sCD4 is closer to that of the V2/V3/C4 
complex  mAbs,  suggesting  that  the  binding  of sCD4  to 
gp120  may reflect  a  combination  of the  effects of both 
groups of mAbs. Since the V2 and V3 loops ofgpl20 ap- 
pear  to  play  a  facilitating  but  not  essential  role  in  HIV 
binding and entry into  CD4 +  cells  (76,  79),  it is unlikely 
that direct sCD4 contact with either of these loops is neces- 
sary to induce  conformational changes in gp120.  Perhaps 
more likely is  the  idea  that  the  high  affinity insertion  of 
sCD4 within  the gp120  binding pocket "opens" the V2/ 
V3/C4 complex, resulting in an increase in the exposure of 
the  V2  and  V3  loops  (47,  48)  and  the  epitopes  for  the 
mAbs 48d and 17b (37,  75). 
The experiments that we describe here were carried out 
on a molecular clone of the cell line adapted HIV-1 isolate, 
LAI, since the majority of neutralizing mAbs that are cur- 
rently available react with  this  clone  in  a  relatively type- 
specific  manner.  To  establish  whether  the  induction  of 
conformational changes in the HIV envelope glycoproteins 
by neutralizing mAbs is a general phenomenon, such stud- 
ies will need to be carried out on other virus isolates.  In this 
respect, we have recently established that V3 mAbs and 48d 
induce  gp41  exposure  in  other  clones  of the  LAI isolate 
(HxB2,  NL43,  and  LAI;  our  unpublished  results).  More 
importantly, the relative ability of neutralizing mAbs to in- 
duce  such  conformational changes  in  HIV-1  isolates  that 
have been isolated and passaged in  PBMCs  (primary iso- 
lates)  needs  to  be investigated.  Such  viruses are relatively 
resistant to antibody neutralization  (58,  73, 74). An inabil- 
ity of mAbs reactive with  the  V2/V3/C4  cluster  on pri- 
mary isolate gp120 to induce gp120-gp41  dissociation may 
explain, at least in part, their resistance to neutralization. 
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